Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
- 11 October 2019
- journal article
- research article
- Published by Elsevier BV in Lung Cancer
- Vol. 138, 79-87
- https://doi.org/10.1016/j.lungcan.2019.10.002
Abstract
No abstract availableKeywords
Funding Information
- Roche
This publication has 25 references indexed in Scilit:
- Impact of Brain Metastases on Quality of Life and Estimated Life Expectancy in Patients with Advanced Non-Small Cell Lung CancerValue in Health, 2014
- Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2014
- The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional studySupportive Care in Cancer, 2013
- Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and GermanyLung Cancer, 2013
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)Annals Of Oncology, 2013
- Isolated central nervous system progression on Crizotinib An Achilles heel of non-small cell lung cancer with EML4-ALK translocation?Cancer Biology & Therapy, 2012
- Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancerCancer, 2009
- Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21Journal of Clinical Oncology, 2006
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trialsEuropean Journal Of Cancer, 1994
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993